FDA refuses to accept Introgen's gene therapy for cancer
This article was originally published in Scrip
Executive Summary
The US FDAhas issued a rare refusal to file decision onIntrogen's gene therapy drug Advexin, which the company filed in June to treat recurrent, refractory head and neck cancer. The company says it intends to appeal against the agency's decision.